PKC ζ (Protein Kinase C zeta) inhibitors are a category of chemical compounds that are designed to selectively target and inhibit the activity of the protein kinase C zeta enzyme. Protein kinase C (PKC) enzymes are a family of serine/threonine kinases that play crucial roles in various cellular processes, including cell growth, differentiation, proliferation, and signal transduction. Among these, PKC ζ is a distinctive member of the atypical PKC isoforms that lacks the classical C1 domain and therefore does not require binding to diacylglycerol (DAG) or phorbol esters for activation. PKC ζ inhibitors exert their effects by specifically binding to the active site of the PKC ζ enzyme, thereby obstructing its catalytic activity. These inhibitors are designed with structural features that enable them to interact with key amino acid residues within the active site, preventing the enzyme from phosphorylating its target substrates.
The specificity of PKC ζ inhibitors arises from their ability to discriminate between various PKC isoforms, targeting only PKC ζ without affecting the activity of other PKC enzymes. By inhibiting PKC ζ, these compounds can influence downstream signaling pathways involved in cellular processes such as cell motility, cell cycle progression, and cytoskeletal reorganization. Researchers have explored the utility of PKC ζ inhibitors as tools for understanding the molecular mechanisms underlying cellular signaling and function. Through the use of these inhibitors, scientists can investigate the specific contributions of PKC ζ to various physiological and pathological processes. Moreover, the availability of selective PKC ζ inhibitors has paved the way for the exploration of applications in a variety of experimental contexts, enabling researchers to dissect intricate cellular pathways and elucidate the roles of PKC ζ in various cellular events. As the understanding of PKC ζ's role in cellular signaling continues to evolve, the development of more potent and specific inhibitors may offer new avenues for investigating the intricacies of cellular regulation and insights into interventions.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
A selective inhibitor of PKCζ, primarily used for certain types of blood cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
A potent inhibitor of conventional and novel PKC isoforms, including PKCζ. It has been used in research to study PKC-mediated signaling pathways. | ||||||
Enzastaurin | 170364-57-5 | sc-364488 sc-364488A sc-364488B | 10 mg 50 mg 200 mg | $254.00 $600.00 $1687.00 | 3 | |
An inhibitor of PKC, including PKCζ, investigated for its potential in regard to cancer due to its ability to target angiogenesis and tumor growth. | ||||||
DAPH-7 | 145915-60-2 | sc-200699 | 1 mg | $71.00 | 1 | |
An experimental PKC inhibitor with potential anti-tumor effects. It has shown inhibitory activity against PKCζ among other PKC isoforms. | ||||||
PKC-412 | 120685-11-2 | sc-200691 sc-200691A | 1 mg 5 mg | $51.00 $112.00 | 10 | |
Although primarily a multi-targeted receptor tyrosine kinase inhibitor, midostaurin also inhibits PKC, including PKCζ. It is used in the research of certain forms of leukemia. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $90.00 $240.00 | 17 | |
A broad-spectrum PKC inhibitor that affects both conventional and novel isoforms, including PKCζ. It has been used in various studies to explore PKC-related functions. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
An experimental immunosuppressive drug with inhibitory effects on several PKC isoforms, including PKCζ. It has been explored for its potential in preventing transplant rejection. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
A commonly used PKC inhibitor that affects multiple isoforms, including PKCζ. It has been employed in numerous research studies to investigate PKC-related pathways. |